Gastrointestinal Cancer | Specialty

Combining BRAF, MEK and EGFR Inhibition in mCRC

January 31st 2019

Lack of Durable Responses in Current Treatment of mCRC

January 31st 2019

Sequencing Strategies in BRAF-Mutated mCRC

January 31st 2019

Prognosticating BRAF-Mutant mCRC

January 31st 2019

Dr. Chao on Practice-Changing Data in Metastatic Gastroesophageal Cancer

January 31st 2019

Joseph Chao, MD, assistant clinical professor, Department of Medical Oncology and Therapeutics Research, City of Hope, discusses practice-changing data in metastatic gastroesophageal (GEJ) cancer.

Dr. Fakih on Durvalumab and Tremelimumab in CRC

January 31st 2019

Marwan Fakih, MD, professor, Department of Medical Oncology and Therapeutics Research, associate director for Clinical Investigations, Comprehensive Cancer Center, medical director, Judy and Bernard Briskin Center for Clinical Research, co-director, Gastrointestinal Cancer Program, and section head, Gastrointestinal Medical Oncology, City of Hope, discusses the combination of durvalumab (Imfinzi) and tremelimumab in patients with metastatic colorectal cancer (mCRC).

Dr. Chung on Sequencing Chemotherapy Regimens in Metastatic Pancreatic Cancer

January 31st 2019

Vincent Chung, MD, associate clinical professor, Department of Medical Oncology and Therapeutics Research, Director Phase I Program, City of Hope, discusses sequencing chemotherapy regimens in patients with metastatic pancreatic cancer.

SM-88 Shows Promise in Advanced Pancreatic Cancer

January 31st 2019

Allyson J. Ocean, MD, discusses the potential impact of SM-88 in the treatment of patients with advanced pancreatic cancer and highlights a platform that patients can use to stay updated on the latest research in the field.

Dougan Discusses Augmenting T-Cell Activity in Pancreatic Cancer

January 29th 2019

Stephanie K. Dougan, PhD, discusses research aimed at assessing ways of augmenting T-cell immunity in pancreatic cancer.

Dr. Picozzi on the Use of SM-88 in Pancreatic Cancer

January 29th 2019

Vincent J. Picozzi, MD, director, Pancreatic Center of Excellence, Virginia Mason Medical Center, discusses the use of SM-88 in pancreatic cancer.

Immune-Oncology Role Continues to Be Refined in GI Cancer

January 28th 2019

Michael J. Overman, MD, highlights new combination agents under investigation for the treatment of patients with GI cancers—specifically CRC—and challenges that still need to be addressed.

Radiation Could Aid in Increasing Pancreatic Cancer Resections

January 28th 2019

Amol K. Narang, MD, discusses recent advances made in the treatment of pancreatic cancer and explained how radiation oncology can be used to provide further clinical benefit to this patient population.

Dr. Shields Discusses Patient Selection Criteria for Adjuvant Therapy in CRC

January 25th 2019

Anthony Shields, MD, PhD, oncologist, Department of Oncology, Molecular Imaging and Diagnostics Program, Karmanos Cancer Institute, discusses patient selection criteria for adjuvant therapy in colorectal cancer (CRC).

Dr. Kasi on the Rising Incidence of CRC

January 24th 2019

Pashtoon M. Kasi, MD, MBBS, MS, an assistant professor of Oncology and senior associate consultant in the Division of Hematology/Oncology, Mayo Clinic, discusses the rising incidence of colorectal cancer (CRC).

FDA Approves 23andMe Consumer Test for Hereditary CRC Syndrome

January 23rd 2019

The FDA has cleared a direct-to-consumer genetic test for a risk report on MUTYH-associated polyposis, a hereditary colorectal cancer syndrome.

Bekaii-Saab Brings Insight to Precision Medicine in GI Cancers

January 23rd 2019

Tanios Bekaii-Saab, MD, discusses ways to further develop precision medicine within the treatment of patients with gastrointestinal cancers.

Ibrutinib Combo Falls Short in Pancreatic Cancer

January 22nd 2019

The frontline combination of ibrutinib (Imbruvica) and nab-paclitaxel (Abraxane)/gemcitabine did not show a statistically significant benefit in progression-free or overall survival versus placebo plus nab-paclitaxel/gemcitabine in patients with metastatic pancreatic cancer.

Choti Sheds Light on Research Developments in Pancreatic Cancer

January 22nd 2019

Michael A. Choti, MD, highlights ongoing developments in the field of pancreatic cancer.

Dr. George on the Phase III TAGS Trial in Gastric/GEJ Cancer

January 22nd 2019

Ben George, MD, assistant professor, Medical College of Wisconsin, discusses the phase III TAGS trial in patients with gastric or gastroesophageal junction (GEJ) cancer.

Dr. Davar on the Rationale for the Combination of Anti-TIM-3 and Anti-PD-1

January 22nd 2019

Diwakar Davar, MD, assistant professor of medicine, Department of Medicine, Hematology/Oncology, University of Pittsburgh, discusses the rationale for the combination of anti-TIM-3 and anti-PD-1 in multiple tumor types.